For these same 41 patients with paired plasma and either tumor tissue or malignant fluid samples obtained after the development of EGFR-TKI resistance, the concordance for mutation detection by ddPCR in plasma relative to that in the paired samples was 78.0% (32/41) (with a sensitivity of 75.8% and specificity of 87.5%) for TKI-sensitizing mutations and 65.9% (27/41) (with a sensitivity of 64.5% and specificity of 70.0%) for T790M (Table 3). Here, EGFR is linked to neoplasm.